[Correlation study between the levels of serum MCP-1,SAA and cognitive function in patients with COPD-OSAHS]

Area of Science:

• Medical Research
• Biomarkers
• Neurology

Background:

• Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea hypopnea syndrome (OSAHS) are common conditions.
• Overlap syndrome (OS) combines both COPD and OSAHS, potentially leading to complex health issues.
• Cognitive impairment is a growing concern in patients with respiratory disorders.

Purpose of the Study:

• To investigate the relationship between serum monocyte chemoattractant protein-1 (MCP-1) and serum amyloid A (SAA) levels and cognitive function in patients with OS.
• To compare cognitive function and inflammatory markers between patients with OS and those with COPD alone.
• To determine if MCP-1 and SAA are associated with cognitive decline in OS.

Main Methods:

• Sixty patients with OS and 33 patients with COPD were enrolled.
• Serum levels of MCP-1 and SAA were measured in all participants.
• Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale.

Main Results:

• OS patients exhibited significantly higher serum levels of MCP-1 and SAA compared to COPD patients.
• The OS group demonstrated significantly lower Montreal scale scores, indicating cognitive impairment.
• A significant negative correlation was observed between Montreal scale scores and serum levels of MCP-1 and SAA in OS patients.

Conclusions:

• Patients with OS show significant cognitive impairment compared to COPD patients.
• OSAHS may be an independent risk factor for cognitive impairment.
• MCP-1 and SAA levels are negatively associated with cognitive function in OS patients, suggesting their role in cognitive impairment pathogenesis.